Date | Price Target | Rating | Analyst |
---|---|---|---|
1/19/2022 | $3.00 → $2.75 | Buy | HC Wainwright & Co. |
7/27/2021 | $3.00 | Buy | Ladenburg Thalmann |
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
ROCKAWAY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research Laboratories (AFRL) presented new results supporting the ability of electroCore's TAC-STIM (nVNS) to accelerate pilot training. The presentation titled "Accelerating Sensorimotor Learning in A Flight Training Simulation Using Transcutaneous Vagus Nerve Stimulation" was presented on Tuesday, August 26th at the 2024 Medical Health System Research Symposium in Orlando, FL. by Dr. Justin Estepp of the Human Effectiveness Directorate of the United States Air Force Research Laboratories (AFRL). The presenta
ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the 26th Annual H.C. Wainwright Global Investment Conference taking place in New York City on September 9-11, 2024. Dan Goldberger, the company's Chief Executive Officer, will participate in a fireside chat on Wednesday, September 11th, at 12:00 PM ET. Mr. Goldberger will also be available for 1x1 meetings the same day. For more information regarding the conference and to register, please visit the conference page here. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectron
LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future. The Group has a portfolio which combines volume growth in 2024 and 2025 from its currently producing royalty portfolio with an extensive pipeline of high-quality development projects that are expected to drive material medium term revenue growth.Marc Bishop Lafleche, Chief Executive Officer of
- SEC Filing
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STIM is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitig
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
**Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report
LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future. The Group has a portfolio which combines volume growth in 2024 and 2025 from its currently producing royalty portfolio with an extensive pipeline of high-quality development projects that are expected to drive material medium term revenue growth.Marc Bishop Lafleche, Chief Executive Officer of
ROCKAWAY, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2024, after the close of the market on Wednesday, August 7, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 7, 4:30 PM EDTDial-In: 877-407-8835 / +1 201-689-8779Conference ID: 13744119Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2024 financial results. Recent Highlights Record revenue of $5.4 million, an increase of 96% over first quarter 2023Launched our direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus™ First Quarter 2024 Financial Results For the quarter ended March 31, 2024, electroCore reported net sales of $5.4 million c
8-K - electroCore, Inc. (0001560258) (Filer)
10-Q - electroCore, Inc. (0001560258) (Filer)
8-K - electroCore, Inc. (0001560258) (Filer)
HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously
Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00
Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00
SC 13D/A - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13D - electroCore, Inc. (0001560258) (Subject)
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan
FAIRFAX, Va. and TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly"), a pioneering artificial intelligence ("AI") company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the appointment of Brian M. Posner to its Board of Directors upon closing of its planned merger with WaveDancer, Inc. ("WaveDancer") (NASDAQ:WAVD). Firefly has entered into a definitive agreement and plan of merger (as amended, the "Merger Agreement") with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing cond
ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company's Board of Directors effective March 15, 2022. The Company also announced that effective March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting. "Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board," said Peter Cuneo